EICHORPublic-registry site landscape for NCT05092503, “JINZHEN for Treatment of Mild to Moderate COVID-19”, a COVID-19 study sponsored by Lianyungang Kanion Group, Ltd.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05092503 (registry record) |
| Study title | JINZHEN for Treatment of Mild to Moderate COVID-19 |
| Official title | A Phase I/Ⅱ Randomized Controlled Proof-of-concept Study to Evaluate the Safety and Efficacy of JINZHEN Granules for Oral Solution in Participants With Mild to Moderate COVID-19 |
| Sponsor | Lianyungang Kanion Group, Ltd. |
| Condition(s) | COVID-19 |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 10 |
| Intervention(s) | JINZHEN Granules for Oral Solution, Placebo |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT05092503.
Eichor generates a preliminary site-risk snapshot for NCT05092503 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
